Immunomodulation therapy of diabetes by oral administration of a surfactin lipopeptide in NOD mice

Highlights • Oral surfactin induces Tregs switching immune response from Th1- to Th2-type. • Tregs attenuates diabetes by secreting IL-10 and TGF-β to suppress activated CD8+ T cells. • Surfactin is a potential immunomodulator for immunotherapy of diabetes.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2014-11, Vol.32 (50), p.6812-6819
Hauptverfasser:	Gao, Zhenqiu, Zhao, Xiuyun, Yang, Tao, Shang, Jun, Shang, Long, Mai, Haizhe, Qi, Gaofu
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Allergy and Immunology Animals Antigens Applied microbiology Atherosclerosis Bacteria Biological and medical sciences Diabetes Diabetes Mellitus, Type 1 - pathology Diabetes Mellitus, Type 1 - prevention & control Disease Disease Models, Animal Enzyme-Linked Immunosorbent Assay Female Flow Cytometry Fundamental and applied biological sciences. Psychology Gram-positive bacteria Heat shock proteins Immune modulation Immune response Immune system Immunoglobulin G - blood Immunohistochemistry Immunologic Factors - administration & dosage Immunomodulation Incidence Insulin Interleukin-10 - blood Lipopeptides - administration & dosage Lymphocytes Mice, Inbred NOD Microbiology Peptides Peptides, Cyclic - administration & dosage Probiotics Rodents Software Surfactin Survival Analysis T-Lymphocyte Subsets - immunology Treatment Outcome Tumor Necrosis Factor-alpha - blood Type 1 diabetes mellitus Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Oral surfactin induces Tregs switching immune response from Th1- to Th2-type. • Tregs attenuates diabetes by secreting IL-10 and TGF-β to suppress activated CD8+ T cells. • Surfactin is a potential immunomodulator for immunotherapy of diabetes.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2014.08.082